Seismic Therapeutic Showcases Contributions at Leading Conferences
Seismic Therapeutic, Inc., a pioneering company based in Massachusetts, is making significant strides in the field of immunology through the utilization of machine learning. The organization is poised to present its innovative pipeline of therapeutics specifically targeting autoimmune and inflammatory diseases at a series of upcoming scientific conferences. With its unique IMPACT platform, Seismic is revolutionizing biologics drug discovery.
Highlights of Upcoming Presentations
During these conferences, Seismic Therapeutic will have multiple presentations and poster sessions highlighting the advances in their therapeutic pipeline and the application of machine learning in drug development.
IMPACT Platform at PEGS Europe
From November 5 to 7, Seismic will participate in the PEGS Europe Protein & Antibody Engineering Summit held in Barcelona. One of the featured presentations will cover methodologies that leverage machine learning to significantly lower the immunogenicity of bacterial proteases affecting pathogenic immunoglobulins. Scheduled for November 6 at 6:45 PM CET, Dr. Ryan Peckner, the Director, Head of Machine Learning, will lead the discussion on this essential topic.
Pipeline Program Presentations at ACR Convergence
The American College of Rheumatology (ACR) Convergence, occurring from November 14 to 19, will also see substantial representation from Seismic Therapeutic. On November 16, Dr. Julia Manasson will present a poster on the preclinical studies of S-1117, an innovative Fc-fused IgG degrading enzyme, aimed at treating chronic autoantibody-mediated diseases. This session will focus on identifying new targets in B cell biology.
Continuing the presentations, Dr. Manasson will also lead a discussion on November 18 about S-4321, a groundbreaking dual-cell bidirectional PD-1:Fc?RIIb selective agonist antibody designed to combat autoimmune conditions.
American Society of Hematology Annual Meeting
At the American Society of Hematology (ASH) Annual Meeting, taking place from December 7 to 10, Seismic will again present research regarding S-1117 on December 8 at 6:00 PM PT. This session will delve into the clinical applications of this engineered enzyme.
Antibody Engineering and Therapeutics Conference
Wrapping up the year, Seismic’s participation at the Antibody Engineering and Therapeutics Conference from December 15 to 19 will include a presentation by Dr. Jyothsna Visweswaraiah on December 18. This talk will cover dual cell bidirectional antibodies specifically designed for autoimmune treatments.
Dr. Visweswaraiah is also co-chairing a critical discussion on Monday, December 16, which will explore themes in both forward and reverse translation medicine, showcasing Seismic's commitment to advancing drug discovery methodologies.
Additionally, there will be several posters presented by key members of the Seismic team regarding the ongoing work on IgG degrading enzyme therapies using the IMPACT platform.
About Seismic Therapeutic
Seismic Therapeutic™ is at the forefront of biotechnology, shifting traditional methodologies for immunology therapy discovery and development through the integration of machine learning. With a robust pipeline showcasing both best-in-class and first-in-class biologics, the company is dedicated to addressing the complexities of dysregulated adaptive immunity. Operating from the innovative biotech hub in Boston, Seismic Therapeutic is backed by a formidable consortium of life sciences investors. For more insights into the past achievements and future directions of the company, please visit www.seismictx.com or connect on social platforms like LinkedIn and X.
Frequently Asked Questions
What is Seismic Therapeutic focused on?
Seismic Therapeutic is dedicated to developing innovative therapies for autoimmune and inflammatory diseases using machine learning technologies.
When and where will Seismic present its research?
Seismic will present at several conferences throughout November and December, including the ACR Convergence and the ASH Annual Meeting.
Who will present at the PEGS Europe Summit?
Dr. Ryan Peckner will present on the application of machine learning in reducing the immunogenicity of bacterial proteases on November 6.
What are dual cell bidirectional antibodies?
These antibodies are engineered therapeutic agents aimed at providing targeted treatments for autoimmune diseases.
How can I learn more about Seismic Therapeutic?
You can learn more about Seismic Therapeutic and its initiatives by visiting their website or following them on social media.
